Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 May 18;53(5):1900235.
doi: 10.1183/13993003.00235-2019. Print 2019 May.

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation

Dave Singh  1 , Leonardo M Fabbri  2   3 , Massimo Corradi  4 , George Georges  5 , Alessandro Guasconi  6 , Stefano Vezzoli  6 , Stefano Petruzzelli  6 , Alberto Papi  2
Affiliations
Randomized Controlled Trial

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation

Dave Singh et al. Eur Respir J. .

Abstract

In patients with symptomatic COPD, severe/very severe airflow limitation, and a history of one moderate (and no severe) exacerbation, ICS-containing triple therapy significantly reduces exacerbation risk overall versus single or double maintenance therapy http://ow.ly/VgJC30o9pXC

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D. Singh reports personal fees from Chiesi, during the conduct of these studies; grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, personal fees from Genentech and Skeypharma, outside the submitted work. Conflict of interest: L.M. Fabbri reports personal fees and non-financial support from AstraZeneca, GSK, Novartis, Menarini, Boehringer Ingelheim, Zambon and Pearl Therapeutics, grants, personal fees and non-financial support from Chiesi, non-financial support from Dompe, outside the submitted work. Conflict of interest: M. Corradi reports grants and personal fees from Chiesi Farmaceutici SpA, outside the submitted work. Conflict of interest: G. Georges was an employee of Chiesi USA, Inc., during the conduct of these studies. Conflict of interest: A. Guasconi was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies. Conflict of interest: S. Vezzoli was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies. Conflict of interest: S. Petruzzelli was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies. Conflict of interest: A. Papi reports fees for board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and TEVA, fees for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon, grants for research from Sanofi, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
a) Adjusted annual rate of moderate-to-severe chronic obstructive pulmonary disease exacerbations (intention-to-treat population). b) Between-treatment differences in St George's Respiratory Questionnaire (SGRQ) total score and forced expiratory volume in 1 s (FEV1) at week 52 and overall, and SGRQ responders at week 52 (intention-to-treat population). Data are adjusted mean differences or odds ratios with 95% confidence intervals and p-values. SGRQ responders are patients with a decrease from baseline in SGRQ total score of at least 4 units. BDP: beclometasone dipropionate; FF: formoterol fumarate; G: glycopyrronium; IND/GLY: indacaterol/glycopyrronium.
See this image and copyright information in PMC

References

    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–1138. - PubMed
    1. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017; 5: 619–626. - PMC - PubMed
    1. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016; 388: 963–973. - PubMed
    1. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919–1929. - PubMed
    1. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076–1084. - PubMed

MeSH terms